Thu, November 8, 2012
Wed, November 7, 2012
Tue, November 6, 2012
Mon, November 5, 2012
Sat, November 3, 2012
Fri, November 2, 2012
Thu, November 1, 2012
Wed, October 31, 2012
Tue, October 30, 2012
Mon, October 29, 2012
Sun, October 28, 2012
Fri, October 26, 2012
Thu, October 25, 2012
Wed, October 24, 2012
Tue, October 23, 2012
Mon, October 22, 2012
Sun, October 21, 2012
Sat, October 20, 2012
Fri, October 19, 2012
Thu, October 18, 2012
Wed, October 17, 2012
Tue, October 16, 2012

Sarepta Therapeutics Announces Third Quarter 2012 Financial Results and Corporate Update Conference Call


//health-fitness.news-articles.net/content/2012/ .. esults-and-corporate-update-conference-call.html
Published in Health and Fitness on by Market Wire   Print publication without navigation



October 30, 2012 16:05 ET

Sarepta Therapeutics Announces Third Quarter 2012 Financial Results and Corporate Update Conference Call

CAMBRIDGE, MA--(Marketwire - Oct 30, 2012) - Sarepta Therapeutics, Inc. (NASDAQ: [ SRPT ]), a developer of innovative RNA-based therapeutics, will report third quarter 2012 financial results after the NASDAQ Global Market closes on Wednesday, November 7, 2012. Subsequently, at 5:00 p.m., Eastern Time (2:00 p.m., Pacific time), Chris Garabedian, Sarepta's President and CEO, will host a conference call to discuss third quarter financial results and to provide a corporate update.

The conference call may be accessed by dialing 800.446.2782 for domestic callers and 847.413.3235 for international callers. The passcode for the call is 33674533. Please specify to the operator that you would like to join the "Sarepta Third Quarter 2012 Earnings Call." The conference call will be webcast live under the events section of Sarepta's website at [ www.sareptatherapeutics.com ] and will be archived there following the call for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta Therapeutics

Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at [ www.sareptatherapeutics.com ].



Publication Contributing Sources

Publication Sponsors
[ Last Sunday ] - Oceanside Rental Gear